CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04665739
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:04.634248+00:00
Published At: 2026-04-22T00:00:00+00:00
Record Updated At: 2026-04-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Lung Neuroendocrine Tumor", "Functioning Lung Neuroendocrine Tumor", "Locally Advanced Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor G1", "Lung Neuroendocrine Tumor G2", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Non-Functioning Lung Neuroendocrine Tumor", "Recurrent Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-22"
protocolSection.identificationModule.nctId: "NCT04665739"
protocolSection.identificationModule.officialTitle: "Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.